Biotech and pharmaceutical executives Robert Mulroy and Dr. Debasish Roychowdhury announced the launch of Partner Therapeutics, or PTx, an oncology company that is focused on the development and commercialization of approved and late-stage therapies.
PTx, based in Boston, USA, is committed to supporting patient care with medicines that improve cancer treatment outcomes and reduce the total cost of care.
Mr. Mulroy and Dr. Roychowdhury are biopharma veterans who combined have overseen the approval and launch of over a dozen new oncology products; the discovery and development of over 50 novel cancer programs; the growth and development of multiple new startups.
Dr. Roychowdhury is a medical oncologist and a proven executive in the pharmaceutical industry with over 15 years of senior management experience and 14 years of patient care, academic research and teaching experience. Prior to PTx, he served as senior vice president and global head of oncology at Sanofi, vice president for clinical development at GlaxoSmithKline, head of the global oncology regulatory group at Eli Lilly and Company, and most recently, the chief medical officer of Seragon, through the company’s acquisition by Roche.
Mr. Mulroy has 25 years of experience in the biopharmaceutical and healthcare sector, having led the development of multiple biotech companies and served as an industry consultant. Prior to PTx he served as co-founder, CEO and director of Merrimack Pharmaceuticals and as director and CEO of Atlantic Bio. He has extensive experience in a comprehensive range of capital raises, strategic transactions, and organizational development spanning research, development and commercial capabilities.
“Debasish and I share a passion for improving patient outcomes in the treatment of cancer,” said Mr. Mulroy. “We formed PTx to address gaps in treatment and improve cost effectiveness of cancer care through a mission-driven organization focused on exceptional execution on behalf of patients.”
PTx will build its product portfolio through the acquisition of programs with the promise to deliver on improved health and economic outcomes. The company plans to operate as an integrated commercial, development and manufacturing organization.